1
|
Liu H, Liu M, Zhao Y, Mo R. Nanomedicine strategies to counteract cancer stemness and chemoresistance. EXPLORATION OF TARGETED ANTI-TUMOR THERAPY 2023; 4:630-656. [PMID: 37720349 PMCID: PMC10501898 DOI: 10.37349/etat.2023.00157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 05/07/2023] [Indexed: 09/19/2023] Open
Abstract
Cancer stem-like cells (CSCs) identified by self-renewal ability and tumor-initiating potential are responsible for tumor recurrence and metastasis in many cancers. Conventional chemotherapy fails to eradicate CSCs that hold a state of dormancy and possess multi-drug resistance. Spurred by the progress of nanotechnology for drug delivery and biomedical applications, nanomedicine has been increasingly developed to tackle stemness-associated chemotherapeutic resistance for cancer therapy. This review focuses on advances in nanomedicine-mediated therapeutic strategies to overcome chemoresistance by specifically targeting CSCs, the combination of chemotherapeutics with chemopotentiators, and programmable controlled drug release. Perspectives from materials and formulations at the nano-scales are specifically surveyed. Future opportunities and challenges are also discussed.
Collapse
Affiliation(s)
- Huayu Liu
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
| | - Mingqi Liu
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
| | - Yanan Zhao
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
| | - Ran Mo
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
| |
Collapse
|
2
|
Ramesh S, Selvakumar P, Ameer MY, Lian S, Abdullah Alzarooni AIM, Ojha S, Mishra A, Tiwari A, Kaushik A, Jung YD, Chouaib S, Lakshmanan VK. State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer. Front Oncol 2023; 13:1059441. [PMID: 36969009 PMCID: PMC10035756 DOI: 10.3389/fonc.2023.1059441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 01/30/2023] [Indexed: 03/11/2023] Open
Abstract
The development of new therapeutic strategies is on the increase for prostate cancer stem cells, owing to current standardized therapies for prostate cancer, including chemotherapy, androgen deprivation therapy (ADT), radiotherapy, and surgery, often failing because of tumor relapse ability. Ultimately, tumor relapse develops into advanced castration-resistant prostate cancer (CRPC), which becomes an irreversible and systemic disease. Hence, early identification of the intracellular components and molecular networks that promote prostate cancer is crucial for disease management and therapeutic intervention. One of the potential therapeutic methods for aggressive prostate cancer is to target prostate cancer stem cells (PCSCs), which appear to be a primary focal point of cancer metastasis and recurrence and are resistant to standardized therapies. PCSCs have also been documented to play a major role in regulating tumorigenesis, sphere formation, and the metastasis ability of prostate cancer with their stemness features. Therefore, the current review highlights the origin and identification of PCSCs and their role in anti-androgen resistance, as well as stemness-related signaling pathways. In addition, the review focuses on the current advanced therapeutic strategies for targeting PCSCs that are helping to prevent prostate cancer initiation and progression, such as microRNAs (miRNAs), nanotechnology, chemotherapy, immunotherapy, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing system, and photothermal ablation (PTA) therapy.
Collapse
Affiliation(s)
- Saravanan Ramesh
- Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Preethi Selvakumar
- Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Mohamed Yazeer Ameer
- Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
| | - Sen Lian
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China
| | | | - Shreesh Ojha
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Anshuman Mishra
- Translational Research & Sustainable Healthcare Management, Institute of Advanced Materials, IAAM, Ulrika, Sweden
| | - Ashutosh Tiwari
- Translational Research & Sustainable Healthcare Management, Institute of Advanced Materials, IAAM, Ulrika, Sweden
| | - Ajeet Kaushik
- NanoBioTech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL, United States
- School of Engineering, University of Petroleum and Energy Studies (UPES), Dehradun, India
| | - Young Do Jung
- Department of Biochemistry, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Salem Chouaib
- Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman, United Arab Emirates
- INSERM UMR1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, Equipe Labellisée par la Ligue Contre le Cancer, EPHE, Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
| | - Vinoth-Kumar Lakshmanan
- Prostate Cancer Biomarker Laboratory, Faculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
- Translational Research & Sustainable Healthcare Management, Institute of Advanced Materials, IAAM, Ulrika, Sweden
- *Correspondence: Vinoth-Kumar Lakshmanan,
| |
Collapse
|
3
|
Sharma S, Mahajan SD, Chevli K, Schwartz SA, Aalinkeel R. Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer. Crit Rev Ther Drug Carrier Syst 2023; 40:69-100. [PMID: 37075068 PMCID: PMC11007628 DOI: 10.1615/critrevtherdrugcarriersyst.2022043827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Treatments for late-stage prostate cancer (CaP) have not been very successful. Frequently, advanced CaP progresses to castration-resistant prostate cancer (CRPC), with 50#37;-70% of patients developing bone metastases. CaP with bone metastasis-associated clinical complications and treatment resistance presents major clinical challenges. Recent advances in the formulation of clinically applicable nanoparticles (NPs) have attracted attention in the fields of medicine and pharmacology with applications to cancer and infectious and neurological diseases. NPs have been rendered biocompatible, pose little to no toxicity to healthy cells and tissues, and are engineered to carry large therapeutic payloads, including chemo- and genetic therapies. Additionally, if required, targeting specificity can be achieved by chemically coupling aptamers, unique peptide ligands, or monoclonal antibodies to the surface of NPs. Encapsulating toxic drugs within NPs and delivering them specifically to their cellular targets overcomes the problem of systemic toxicity. Encapsulating highly labile genetic therapeutics such as RNA within NPs provides a protective environment for the payload during parenteral administration. The loading efficiencies of NPs have been maximized while the controlled their therapeutic cargos has been released. Theranostic ("treat and see") NPs have developed combining therapy with imaging capabilities to provide real-time, image-guided monitoring of the delivery of their therapeutic payloads. All of these NP accomplishments have been applied to the nanotherapy of late-stage CaP, offering a new opportunity for a previously dismal prognosis. This article gives an update on current developments in the use of nanotechnology for treating late-stage, castration-resistant CaP.
Collapse
Affiliation(s)
- Satish Sharma
- Department of Urology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
| | - Supriya D. Mahajan
- Department of Medicine, Division of Allergy, Immunology and Rheumatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
| | - Kent Chevli
- Department of Urology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
| | - Stanley A. Schwartz
- Department of Urology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
- Department of Medicine, Division of Allergy, Immunology and Rheumatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
| | - Ravikumar Aalinkeel
- Department of Urology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
- Department of Medicine, Division of Allergy, Immunology and Rheumatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY
| |
Collapse
|
4
|
Al-Sawaftah NM, Abusamra RH, Husseini GA. Carbohydrate-functionalized Liposomes in Cancer Therapy. CURRENT CANCER THERAPY REVIEWS 2021. [DOI: 10.2174/1573394716999200626144921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Existing cancer treatments are often accompanied by adverse side effects that can greatly
reduce the quality of life of cancer patients; this sets the platform for the development and application
of nanocarrier-based platforms for the delivery of anticancer drugs. Among these nanocarriers,
liposomes have demonstrated excellent potential in drug delivery applications. Furthermore,
the overexpression of certain receptors on cancer cells has led to the development of active targeting
approaches where liposome surfaces are decorated with ligands against these receptors. Given
the central role that sugars play in cancer biology, more and more researchers are integrating “glycoscience”
into their anticancer therapeutic designs. Carbohydrate functionalized liposomes present
an attractive drug delivery system due to their biocompatibility, biodegradability, low toxicity,
and specific cell targeting ability. This review presents an overview of the preparation methods,
characterization, evaluation, and applications of carbohydrate functionalized liposomes in cancer
therapy.
Collapse
Affiliation(s)
- Nour M. Al-Sawaftah
- Department of Chemical Engineering, American University of Sharjah, Sharjah, United Arab Emirates
| | - Rand H. Abusamra
- Department of Chemical Engineering, American University of Sharjah, Sharjah, United Arab Emirates
| | - Ghaleb A. Husseini
- Department of Chemical Engineering, American University of Sharjah, Sharjah, United Arab Emirates
| |
Collapse
|
5
|
Vicente‐Ruiz S, Serrano‐Martí A, Armiñán A, Vicent MJ. Nanomedicine for the Treatment of Advanced Prostate Cancer. ADVANCED THERAPEUTICS 2020. [DOI: 10.1002/adtp.202000136] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Sonia Vicente‐Ruiz
- Polymer Therapeutics Laboratory Centro de Investigación Príncipe Felipe Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Antoni Serrano‐Martí
- Polymer Therapeutics Laboratory Centro de Investigación Príncipe Felipe Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - Ana Armiñán
- Polymer Therapeutics Laboratory Centro de Investigación Príncipe Felipe Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| | - María J. Vicent
- Polymer Therapeutics Laboratory Centro de Investigación Príncipe Felipe Av. Eduardo Primo Yúfera 3 Valencia 46012 Spain
| |
Collapse
|
6
|
Esfandyari-Manesh M, Abdi M, Talasaz AH, Ebrahimi SM, Atyabi F, Dinarvand R. S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles containing Imatinib for targeting drug delivery to atherosclerotic plaques. ACTA ACUST UNITED AC 2020; 28:131-138. [PMID: 31919789 DOI: 10.1007/s40199-019-00324-w] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Accepted: 12/17/2019] [Indexed: 01/06/2023]
Abstract
BACKGROUND Imatinib is a platelet-derived growth factor receptor (PDGFR) inhibitor with very low water solubility. Previous studies in atherosclerosis have shown that PDGFR activity has an egregious effect on vascular disease and progression of atherosclerosis. Specific ligands of atherosclerotic plaques can be used for targeting of nanoparticles. Studies in atherosclerosis proved that stabilin-2 is a glycoprotein which exists abundantly in atherosclerotic plaques and it is produced from both macrophages and endothelial cells. OBJECTIVES The objective of this study is the targeting drug delivery to atherosclerotic plaques by using imatinib-loaded nanoparticles modified by S2P peptide. METHODS The imatinib-loaded nanoparticles were fabricated through a modified emulsion/solvent evaporation technique. After fabricating PLGA nanoparticles, maleimide PEG was used as linker between PLGA nanoparticles and S2P peptide. Because of presence cysteine in both side of S2P peptide, maleimide formed a thiolether linkage by thiol group of cysteine. Then the physicochemical analysis like H-NMR, FT-IR, DSC, SEM, particle size, zeta potential, and drug release were studied. RESULTS Stabilin-2 peptide with sequence of CRTLTVRKC is a specific ligand to stabilin-2, so it was synthesized for using as the targeting agent for atherosclerosis. S2P peptide conjugation to the surface of nanoparticles was proved by H-NMR and FT-IR, and the percentage of S2P peptide in nanoparticles was 1.3%. The final nanoparticles were spherical and their size were 183 nm. The loading capacity of the imatinib-loaded nanoparticles was 5.05%. The sustained release profile was observed for peptide targeted nanoparticles. CONCLUSION The chosen method was simple, reproducible, and specific in peptide conjugation of nanoparticles for targeting delivery to atherosclerotic regions. Graphical abstract .
Collapse
Affiliation(s)
- Mehdi Esfandyari-Manesh
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Masoome Abdi
- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Azita Hajhossein Talasaz
- Department of Clinical Pharmacy, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Fatemeh Atyabi
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.,Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Rassoul Dinarvand
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. .,Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
7
|
Cheng C, Meng Y, Zhang Z, Li Y, Liu C, Zhang Q. pH responsible and fluorescent Cy5.5-PEG-g-A-HA/CDDP complex nanoparticles: synthesis, characterization, and application for targeted drug delivery. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2019; 30:58. [PMID: 31127370 DOI: 10.1007/s10856-019-6260-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Accepted: 05/06/2019] [Indexed: 05/25/2023]
Abstract
Clinical application of cisplatin (CDDP) against various solid tumors is often limited due to its poor selectivity and severe side effect. Considering this, in our study, CDDP was incorporated in fluorescent PEG amine grafted aldehyde hyaluronic acid by imine bond and metal ion coordination bond linking and formed a complex, the complex was then self-assembled into nanoparticles in water simply. FT-IR, XRD, DLS and SEM analysis demonstrated that the nanoparticles were prepared successfully and exhibited a spherical structure with size ranged from 216.4 to 372.3 nm in diameter. CDDP releasing from the nanoparticles was in a controlled manner, and had faster release rate at lower pH, indicating the nanoparticles were responsive to tumor micro-acid environment. Since fluorescent Cy5.5 and targeting hyaluronic acid existed on the surface of the nanoparticles, CLSM images clearly showed that the nanoparticles could target and internalize into HeLa cells, and then inhibited the growth of HeLa cells. In addition, MTT, AO-EB staining, and hemolysis assay showed that the nanoparticles had good cyto-/hemo-compatibility. Hence, the nanoparticles had the potential to be used for cancer therapy and diagnosis. The further in vivo experiment will be shown in the next work. pH responsible and fluorescent Cy5.5-PEG-g-A-HA/CDDP complex nanoparticles were facilely fabricated for controlled and targeted delivery of CDDP.
Collapse
Affiliation(s)
- Cui Cheng
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, P.R. China.
| | - Yabin Meng
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, P.R. China
| | - Zhihong Zhang
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, P.R. China
| | - Ya Li
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, P.R. China
| | - Chun Liu
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, P.R. China
| | - Qiqing Zhang
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, P.R. China
| |
Collapse
|
8
|
Zhang X, Huang G, Huang H. The glyconanoparticle as carrier for drug delivery. Drug Deliv 2018; 25:1840-1845. [PMID: 30799659 PMCID: PMC7011877 DOI: 10.1080/10717544.2018.1519001] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Revised: 08/25/2018] [Accepted: 08/30/2018] [Indexed: 02/02/2023] Open
Abstract
The glyconanoparticle (GlycoNP) has multiple effects and has important applications in drug delivery and bioimaging. It not only has the advantages of nano drug delivery system but also utilizes the characteristics of multivalent interaction of sugar, which greatly improves the targeting of drug delivery. Herein, the application of GlycoNP in drug delivery was analyzed and discussed, the solution to its problem was proposed, and its prospects were forecasted.
Collapse
Affiliation(s)
- Xueqin Zhang
- Active Carbohydrate Research Institute, Chongqing Normal University, Chongqing, China
| | - Gangliang Huang
- Active Carbohydrate Research Institute, Chongqing Normal University, Chongqing, China
| | - Hualiang Huang
- School of Chemistry and Environmental Engineering, Wuhan Institute of Technology, Wuhan, China
| |
Collapse
|
9
|
Triple stimuli-responsive keratin nanoparticles as carriers for drug and potential nitric oxide release. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2018; 91:606-614. [DOI: 10.1016/j.msec.2018.05.073] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 04/08/2018] [Accepted: 05/25/2018] [Indexed: 11/19/2022]
|
10
|
You L, Liu X, Fang Z, Xu Q, Zhang Q. Synthesis of multifunctional Fe 3O 4@PLGA-PEG nano-niosomes as a targeting carrier for treatment of cervical cancer. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2018; 94:291-302. [PMID: 30423711 DOI: 10.1016/j.msec.2018.09.044] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Revised: 05/25/2018] [Accepted: 09/15/2018] [Indexed: 11/27/2022]
Abstract
A new folic acid (FA)-conjugated poly (lactic-co-glycolicacid) (PLGA)-polyethylene glycol (PEG) nano-noisome was prepared. The noisome was employed as a drug delivery system to load curcumin (Cur) as a model drug and fluorescent probe for cervical cancer therapy and cell imaging. The Fe3O4@PLGA-PEG@FA noisomes were prepared through facile emulsion solvent evaporation and conjugation chemistry method, possessing the properties of high rapid magnetic separation and targeting character. X-ray photoelectron spectroscopy (XRD), Fourier transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), thermogravimetric analysis (TGA), and vibrating sample magnetometer (VSM) were adopted to characterize the chemical structure and properties of these niosomes. MTT assay revealed that the blank noisomes exhibited excellent biocompatibility. The in vitro drug loading and release behavior studier showed the as prepared nano-noisome presented ultrahigh performance as drug carrier. The confocal laser scanning microscopy (CLSM) and flow cytometry (FCM) experiments demonstrated that Cur-loaded Fe3O4@PLGA-PEG@FA niosomes achieved significantly high targeting efficiency for cervical cancer. Additionally, the FA-targeted niosomes exhibited higher antitumor efficiency than free Cur. Cell morphology, the mitochondrial membrane potential and cell cycle changes indicated that Cur-loaded niosomes induced HeLa229 cells to apoptosis by destroying mitochondrion of cervical tumor cells, simultaneously changing nuclear morphology and blocking tumor cell proliferation. These results demonstrate that Fe3O4@PLGA-PEG@FA noisomes have promising applications as targeted drug delivery system for sustained drug release in cancer treatment.
Collapse
Affiliation(s)
- Lijun You
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou 350001, China.
| | - Xiaocui Liu
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou 350001, China
| | - Zhexiang Fang
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou 350001, China
| | - Qianhui Xu
- College of Oral Medicine, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Qiqing Zhang
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou 350001, China.
| |
Collapse
|
11
|
Tang Q, Huang G. Preparation and applications of glyconanoparticles. Int J Biol Macromol 2018; 116:927-930. [PMID: 29777808 DOI: 10.1016/j.ijbiomac.2018.05.103] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Revised: 05/08/2018] [Accepted: 05/15/2018] [Indexed: 01/28/2023]
Abstract
The glyconanoparticle can be used to construct biological cell models that are similar to the expression of carbohydrates on the surface of cells, and it has become excellent research tools in glycobiology, biopharmaceuticals, and materials science. With the deepening of research, glyconanoparticle has broad application prospects in drug delivery, biomedical imaging, diagnosis and treatment because its preparation is simple, and it has the unique physical, chemical and biological properties. The preparation of glyconanoparticles and their applications were summarized and discussed here.
Collapse
Affiliation(s)
- Qilin Tang
- Active Carbohydrate Research Institute, Chongqing Normal University, Chongqing, 401331, China
| | - Gangliang Huang
- Active Carbohydrate Research Institute, Chongqing Normal University, Chongqing, 401331, China.
| |
Collapse
|
12
|
Roudi R, Ebrahimi M, Shariftabrizi A, Madjd Z. Cancer stem cell research in Iran: potentials and challenges. Future Oncol 2017; 13:1809-1826. [PMID: 28776391 DOI: 10.2217/fon-2017-0091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Treatment modalities can reduce cancer-related mortality; however, a majority of patients develop drug resistance, metastasis and relapse. It has been proposed that tumorigenic characteristics of tumors are related to a proportion of cancer cells, termed cancer stem cells (CSCs). Following the first evidence regarding the existence of CSC population in acute myeloid leukemia in 1997, publications in CSCs field showed an explosive trend in all cancer types around the world. First research paper in the field of CSCs in Iran was published in 2004 on prostate cancer. Subsequently, an annual number of publications in the field of CSCs displayed a rapidly growing trend. Therefore, in the current review, we have presented a comprehensive evaluation of the CSCs research in Iran.
Collapse
Affiliation(s)
- Raheleh Roudi
- Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Marzieh Ebrahimi
- Department of Stem Cells & Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, ACECR, Tehran, Iran
| | - Ahmad Shariftabrizi
- Department of Nuclear Medicine & Molecular Imaging, State University of New York at Buffalo, Buffalo, NY 14214, USA
| | - Zahra Madjd
- Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.,Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
13
|
Qin W, Zheng Y, Qian BZ, Zhao M. Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling. Front Pharmacol 2017; 8:153. [PMID: 28400729 PMCID: PMC5368180 DOI: 10.3389/fphar.2017.00153] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 03/09/2017] [Indexed: 12/19/2022] Open
Abstract
Prostate cancer is the most common cancer among men worldwide. However, current treatments for prostate cancer patients in advanced stage often fail because of relapse. Prostate cancer stem cells (PCSCs) are resistant to most standard therapies, and are considered to be a major mechanism of cancer metastasis and recurrence. In this review, we summarized current understanding of PCSCs and their self-renewal signaling pathways with a specific focus on Wnt signaling. Although multiple Wnt inhibitors have been developed to target PCSCs, their application is still limited by inefficient delivery and toxicity in vivo. Recently, nanotechnology has opened a new avenue for cancer drug delivery, which significantly increases specificity and reduces toxicity. These nanotechnology-based drug delivery methods showed great potential in targeting PCSCs. Here, we summarized current advancement of nanotechnology-based therapeutic strategies for targeting PCSCs and highlighted the challenges and perspectives in designing future therapies to eliminate PCSCs.
Collapse
Affiliation(s)
- Wei Qin
- The Third Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen UniversityGuangzhou, China; Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen UniversityGuangzhou, China
| | - Yongjiang Zheng
- The Third Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University Guangzhou, China
| | - Bin-Zhi Qian
- Edinburgh Cancer Research UK Centre and MRC University of Edinburgh Centre for Reproductive Health, University of Edinburgh Edinburgh, UK
| | - Meng Zhao
- The Third Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen UniversityGuangzhou, China; Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen UniversityGuangzhou, China; Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen UniversityGuangzhou, China
| |
Collapse
|
14
|
Shabani Ravari N, Goodarzi N, Alvandifar F, Amini M, Souri E, Khoshayand MR, Hadavand Mirzaie Z, Atyabi F, Dinarvand R. Fabrication and biological evaluation of chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles in CD44(+) cancer cells. ACTA ACUST UNITED AC 2016; 24:21. [PMID: 27473554 PMCID: PMC4966701 DOI: 10.1186/s40199-016-0160-y] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Accepted: 07/21/2016] [Indexed: 11/28/2022]
Abstract
Background Hyaluronic acid (HA) has been used for target-specific drug delivery because of strong affinity to CD44, a marker in which overexpressed in cancer cells and cancer stem cells. Conjugation of HA to the cytotoxic agents via active targeting can improve efficacy, biodistribution, and water solubility. To be able to benefit from passive targeting as well, a nanoparticulate system by counter ion using a polycation like chitosan may lead to a perfect delivery system. Methods Water soluble Hyaluronic acid-Docetaxel (HA-DTX) conjugate was prepared and used to formulate chitosan-coated HA-DTX nanoparticles by polyelectrolyte complex (PEC) method and optimized using Box-Behnken design. Biological evaluation of nanoparticles was done in CD44+ cancer cells. Results and discussion Biological evaluation of optimized formula showed IC50 of nanoparticles for 4 T1 and MCF-7 cell lines were 45.34 μM and 354.25 μM against 233.8 μM and 625.9 μM for DTX, respectively with increased cellular uptake showed by inverted confocal microscope. Conclusion Chitosan-coated HA-DTX nanoparticles were more effective against CD44+ cells than free DTX. Graphical abstract Chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles fabricated and evaluated in CD44+ cancer cells![]()
Collapse
Affiliation(s)
- Nazanin Shabani Ravari
- Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran
| | - Navid Goodarzi
- Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
| | - Farhad Alvandifar
- Nanomedicine and Biomaterial Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohsen Amini
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Effat Souri
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Reza Khoshayand
- Department of Drug and Food Control, Faculty of Pharmacy and Pharmaceutical Quality Assurance Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Zahra Hadavand Mirzaie
- Nanomedicine and Biomaterial Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Atyabi
- Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran.,Nanomedicine and Biomaterial Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Rassoul Dinarvand
- Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran.,Nanomedicine and Biomaterial Lab, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
15
|
Lakshmanan VK. Therapeutic efficacy of nanomedicines for prostate cancer: An update. Investig Clin Urol 2016; 57:21-9. [PMID: 26966723 PMCID: PMC4778751 DOI: 10.4111/icu.2016.57.1.21] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 12/09/2015] [Indexed: 02/06/2023] Open
Abstract
Recent advances in cancer nanomedicine have attracted remarkable attention in medical sectors. Pharmacologic research on nanomedicines, including targeted cancer therapy, has increased dramatically in the past 5 years. The success stories of nanomedicines in the clinical field include the fabrication of nanomedicines that show maximum loading efficiency into carriers, maximal release kinetics, and minimum toxicity to healthy cells. Nanoparticle-mediated medicines have been developed to specifically target prostate cancer tissue by use of aptamers, antibody targeting, and sustained release of nanomedicines in a dose- and time-dependent manner. Nanomedicines have been developed for therapeutic application in combination with image-guided therapy in real time. The scope of one of these nanomedicines, Abraxane (paclitaxel), may be extended to prostate cancer therapeutic applications for better quality of patient life and longer survival. This review provides an update on the latest directions and developments in nanomedicines for prostate cancer.
Collapse
Affiliation(s)
- Vinoth-Kumar Lakshmanan
- Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju, Korea
| |
Collapse
|
16
|
Fang Z, Wan LY, Chu LY, Zhang YQ, Wu JF. 'Smart' nanoparticles as drug delivery systems for applications in tumor therapy. Expert Opin Drug Deliv 2015; 12:1943-53. [PMID: 26193970 DOI: 10.1517/17425247.2015.1071352] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
INTRODUCTION In the therapy of clinical diseases such as cancer, it is important to deliver drugs directly to tumor sites in order to maximize local drug concentration and reduce side effects. This objective may be realized by using 'smart' nanoparticles (NPs) as drug delivery systems, because they enable dramatic conformational changes in response to specific physical/chemical stimuli from the diseased cells for targeted and controlled drug release. AREAS COVERED In this review, we first briefly summarize the characteristics of 'smart' NPs as drug delivery systems in medical therapy, and then discuss their targeting transport, transmembrane and endosomal escape behaviors. Lastly, we focus on the applications of 'smart' NPs as drug delivery systems for tumor therapy. EXPERT OPINION Biodegradable 'smart' NPs have the potential to achieve maximum efficacy and drug availability at the desired sites, and reduce the harmful side effects for healthy tissues in tumor therapy. It is necessary to select appropriate NPs and modify their characteristics according to treatment strategies of tumor therapy.
Collapse
Affiliation(s)
- Zhi Fang
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ;
| | - Lin-Yan Wan
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ; .,b 2 China Three Gorges University, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy , Yichang, Hubei 443002, China
| | - Liang-Yin Chu
- c 3 Sichuan University, School of Chemical Engineering , Chengdu, Sichuan 610065, China.,d 4 Sichuan University, Collaborative Innovation Center for Biomaterials Science and Technology, State Key Laboratory of Polymer Materials Engineering , Chengdu, Sichuan 610065, China
| | - Yan-Qiong Zhang
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ;
| | - Jiang-Feng Wu
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ; .,b 2 China Three Gorges University, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy , Yichang, Hubei 443002, China
| |
Collapse
|
17
|
Zhi X, Wang Y, Li P, Yuan J, Shen J. Preparation of keratin/chlorhexidine complex nanoparticles for long-term and dual stimuli-responsive release. RSC Adv 2015. [DOI: 10.1039/c5ra16253j] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Nanoscale polyion complex formation via the electrostatic complexation of a polyelectrolyte and a charged drug is the most convenient method for building a drug delivery system that simultaneously realizes the carrier preparation and drug embedding.
Collapse
Affiliation(s)
- Xuelian Zhi
- Jiangsu Key Laboratory of Biofunctional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing 210023
- China
| | - Yanfang Wang
- Jiangsu Key Laboratory of Biofunctional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing 210023
- China
| | - Pengfei Li
- Jiangsu Key Laboratory of Biofunctional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing 210023
- China
| | - Jiang Yuan
- Jiangsu Key Laboratory of Biofunctional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing 210023
- China
| | - Jian Shen
- Jiangsu Key Laboratory of Biofunctional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing 210023
- China
| |
Collapse
|